| dc.description.abstract | The introduction of biosimilars to health care markets across the globe has had some success
in increasing competition and improving the cost of healthcare. While savings are important
for driving the biosimilar uptake, this is not the only consideration for the growth of
biosimilars onto emerging markets.
A systematic review of the literature to assess the growth of biosimilars onto the emerging
market was conducted using the following data sources: PubMed, Website of the Generics and
Biosimilars Initiative (GaBI) journal, ProQuest, Google Scholar. Studies that provided evidence
of biosimilars onto the emerging market through surveys and other sources of existing data
were included. The systematic review process followed Wichor et al. (2018) and the PRISMA
checklist (PRISMA, 2009). The search strategy for the review provided a total of 71studies,
which underwent title, abstract and full text review to give 20 articles that fit the inclusion
criteria for the aimed study. A quality assessment was conducted on the 20 articles and by using
the Hawker et al. (2002) quality tool and directed research questions to set variables, the data
analysis of 13 articles emerged.
The included studies agreed on the growth of biosimilars onto the emerging market and on the
switch to biosimilars to improve access to therapies. However, International Nonproprietary
Name (INN) and physician confidence were still considered as hurdles. The two most
successful drivers of the growth of biosimilars onto the emerging market based on this review
was certainly the regulation of the process followed by the cost of biosimilars.
To conclude, data analysis of 13 articles determined that the general perception of using
biosimilars in emerging markets is positive. However, for successful integration into routine
healthcare and uptake into these markets, there must be a direct focus on the regulation of
Biosimilars | en_US |
